Clinical trial • Phase I • Oncology

DS9051b for Adrenocortical carcinoma | Metastatic castration-resistant prostate cancer

Phase I trial of DS9051b for Adrenocortical carcinoma | Metastatic castration-resistant prostate cancer. 25 participants.

Overview

Trial Therapeutic Area
Oncology
Trial Disease
Adrenocortical carcinoma | Metastatic castration-resistant prostate cancer
Trial Stage
Phase I

Key dates

Initial CTIS Submission Date
17-09-2025
First CTIS Authorization Date
03-12-2025

Trial design

Phase I trial across 2 sites in France.

Target Sample Size
25

Recruitment

Planned Sample Size
25
Recruitment Window Months
26

Geography

Total Number Of Sites
2
Total Number Of Participants
25

France

Earliest CTIS Part Ii Submission Date
30-09-2025
Latest Decision Or Authorization Date
07-01-2026
Processing Time Days
99
Number Of Sites
2
Number Of Participants
15

Sites

Site Name
Centre Oscar Lambret
Department Name
Oncologie Médical
Principal Investigator Name
Karim FIZAZI
Principal Investigator Email
k-fizazi@o-lambret.fr
Contact Person Name
Karim FIZAZI
Contact Person Email
k-fizazi@o-lambret.fr
Site Name
Oncopole Claudius Regaud
Department Name
Oncologie Médical
Principal Investigator Name
Loïc MOUREY
Principal Investigator Email
mourey.loic@iuct-oncopole.fr
Contact Person Name
Loïc MOUREY
Contact Person Email
mourey.loic@iuct-oncopole.fr

Sponsor

Primary sponsor

Full Name
Daiichi Sankyo Inc.
Organisation Type
Pharmaceutical company
Country Of Registered Address
United States

Investigational products

Investigational Product Name
DS9051b
First In Human
Yes

Related trials

Other published trials that may interest you.